LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX) today announced that preclinical data from a novel gadolinium-based collagen-specific contrast agent, EP-3533, was featured in a poster presentation at the Society for Cardiovascular Magnetic Resonance Imaging Tenth Annual Scientific Meeting in Rome, Italy. In a mouse model of myocardial infarction (heart attack), EP-3533-enhanced magnetic resonance imaging (MRI) was able to differentiate healthy, viable myocardium (heart muscle) from non-viable, infarcted myocardium.
